Skip to main content
SpringerLink
Log in

Anti-Angiogenese mit Trebananib

Epitheliales Ovarialkarzinom

  • neues aus der forschung
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Monk BJ et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, muticentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(8): 799–808.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Christina Berndt

Authors
  1. Christina Berndt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berndt, C. Anti-Angiogenese mit Trebananib. Info Onkol. 17, 32 (2014). https://doi.org/10.1007/s15004-014-0972-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0972-1

Search

Navigation